# DermaSensor, Inc.

> DermaSensor is a Miami-based medical device company that makes the first FDA-cleared, AI-powered handheld device for detecting all three common skin cancers - melanoma, basal cell carcinoma, and squamous cell carcinoma - at the point of care. Using elastic scattering spectroscopy and a machine learning algorithm trained on thousands of biopsy-confirmed lesions, the device gives primary care physicians a real-time, non-invasive read on whether a suspicious skin lesion warrants further evaluation, helping close the gap created by a shortage of dermatologists.

- **Founded:** 2009
- **Headquarters:** Miami, Florida, United States
- **Founders:** Maurice Ferre (Co-founder and Chairman), Christopher Dewey (Co-founder and Director), Cody Simmons (Co-founder and CEO (joined 2014))
- **Team size:** ~33 employees
- **Products:** DermaSensor Device
- **Notable:** First AI-powered medical device cleared by the FDA to detect all three common skin cancers (melanoma, basal cell carcinoma, squamous cell carcinoma)., Granted FDA Breakthrough Device Designation and cleared via De Novo pathway., DERM-SUCCESS pivotal study reported ~96% device sensitivity for skin cancers in primary care (vs. ~83% for PCPs).

## Products & services

- **DermaSensor Device** — A handheld, non-invasive, AI-powered device that uses elastic scattering spectroscopy (ESS) to evaluate suspicious skin lesions. It shines hundreds of light wavelengths into a lesion, reads how light scatters off cellular and subcellular structures, and runs the spectral data through a machine learning algorithm to return a real-time 'Investigate Further' or 'Monitor' result in seconds. FDA-cleared to assess for melanoma, basal cell carcinoma, and squamous cell carcinoma.

## Achievements

- First AI-powered medical device cleared by the FDA to detect all three common skin cancers (melanoma, basal cell carcinoma, squamous cell carcinoma).
- Granted FDA Breakthrough Device Designation and cleared via De Novo pathway.
- DERM-SUCCESS pivotal study reported ~96% device sensitivity for skin cancers in primary care (vs. ~83% for PCPs).
- Helped primary care physicians cut missed skin cancer referrals roughly in half.
- Earned CE mark for the skin cancer detection device.
- Over 20,000 skin lesions scanned with ~117% average quarterly growth since U.S. commercial launch.

## Latest updates

- **2025-10** — Raised $16M Series B to scale the device into more primary care practices.
- **2024** — Received FDA clearance as the first AI-powered device to detect all three common skin cancers.
- **2023** — Unveiled DERM-SUCCESS study results and study data across skin tones in over 1,000 patients.

## Links

- Website: https://dermasensor.com
- LinkedIn: http://www.linkedin.com/company/dermasensor
- Twitter/X: http://www.twitter.com/dermasensor
- Facebook: http://www.facebook.com/dermasensor

---

Profile page: https://yespress.io/dermasensor-inc-ai-powered-skin-cancer-detection-device
Published by YesPress — https://yespress.io
Last updated: 2026-06-15